AbbVie Hikes Quarterly Dividend 35% (ABBV)

By: ,


Since its divestiture from Abbot Labs in 2013, AbbVie, Inc. (NYSE:ABBV) has been rewarding its shareholders with rising dividends and steady asset appreciation.

For the current quarter, the company hiked its dividend payout by one third and offers a 3.4% yield, which is almost 40% above the average yield of its peers in the Drug Manufacturers market segment. In addition to the better-than-average yield, the company boosted its annual payout every year since 2013.

The company’s share price rose in the past 12 months and combined with the dividend income to reward shareholders with a total return of more than 75%. AbbVie will distribute its next cash dividend on the May 15, 2018, pay date to all its shareholders of record prior to the April 12, 2018, ex-dividend date.



AbbVie, Inc.. (NYSE:ABBV)

Headquartered in North Chicago, Illinois, and founded in 2013, when Abbot Labs (NYSE:ABT) divested its proprietary pharmaceutical business, AbbVie Inc. discovers, develops, manufactures and sells pharmaceutical products. The most prominent pharmaceutical brands in the company’s current portfolio are HUMIRA for the treatment of autoimmune diseases, IMBRUVICA for the treatment of patients with chronic lymphocytic leukemia and VIEKIRA PAK for the treatment of adults with hepatitis C. Additionally, AbbVie offers pharmaceutical treatments for HIV, hypothyroidism, prostate cancer, endometriosis, anemia, Parkinson’s disease and multiple sclerosis, as well as treatments for testosterone replacement therapy and pancreatic enzyme therapy for exocrine pancreatic insufficiency.

The company boosted its quarterly dividend payout 35.2% from the previous period’s $0.71 to the current $0.96 quarterly distribution. This new quarterly distribution is equivalent to a $3.84 annualized payout and yields 3.4%, which is 10% above the company’s average yield over the past five years.

The company’s current 3.4% yield exceeds the simple average dividend yield of the Drug Manufacturers market segment by nearly 40% and it is almost four times higher than the 0.7% average dividend yield of the entire Health Care sector. ABBV’s current yield is even 3% higher than the 3.3% average yield of only dividend-paying companies in the Drug Manufacturers segment.

The company has hiked its annual dividend every year since it started operating as an independent business entity in 2013. Over the past five years, the company raised its annual payout at an average growth rate of 19.1% per year. Because of this high growth rate, the current $3.84 annualized payout is 140% higher than the initial annual dividend payout of $1.60 in 2013.

AbbVie, Inc. is only five years old, but I consider the company as one of the Dividend Aristocrats, which are S&P 500 companies with a market capitalization exceeding $3 billion and more than 25 consecutive years of dividend hikes. Here is my reasoning. The company’s former parent – Abbot Labs – paid rising dividends for 41 consecutive years prior to the 2013 divestiture of AbbVie. In 2013, Abbot Labs lowered its total annual dividend payout to $0.56, compared to $2.01 in 2012. However, AbbVie paid a $1.66 total dividend in 2013, for a combined dividend of $2.16. This amount was higher than Abbot Labs’ 2012 distribution of $2.01. Since 2013, both continued to hike their annual dividends every year. Therefore, I consider their records of consecutive dividend hikes as continuations of Abbot Labs’ 41-year rising dividends record up to 2013.


AbbVie’s share price has been rising steadily since the company’s formation in 2013 and even accelerated its growth rate in August 2017. The share price declined 3% at the onset of the trailing 12-month period and reached its 52-week low of $63.45 on April 19, 2018. However, after bottoming out in mid-April, the share price nearly doubled before reaching its 52-week high of $123.21 on January 26, 2018.

During the market sell-off in early February, AbbVie’s share price pulled back only 11%, while many other stocks dropped twice that rate. Since that small pullback, AbbVie’s share price resumed its climb and closed on March 20, 2018, at $112.65, which is approximately 8.5% short of the January peak. However, the current closing price is 72.4% above its price from one year earlier, 77.5% higher than the 52-week low from April 2017 and 176% higher since the company became its own business entity in 2013.

AbbVie keeps rewarding its shareholders with a combination of fast rising dividend income and significant share price growth for combined total returns of 76%, 96% and 222% over the past one year, three years and five years, respectively.

Dividend increases and decreases, new dividend announcements, dividend suspensions and other dividend changes occur daily. To make sure you don’t miss any important announcements, sign up for our E-mail Alerts. Let us do the hard work of gathering the data and sending the relevant information directly to your inbox.

In addition to E-mail Alerts, you will have access to our powerful research tools. Take a quick video tour of the tools suite.



Ned Piplovic

Connect with Ned Piplovic

Ned Piplovic
Ned Piplovic, formerly an assistant editor of website content at Eagle Financial Publications, is an economic analyst and editor at Skousen Publishing. Additionally, Ned is also a teaching assistant at Chapman University to Mark Skousen, PhD, a free-market economist and Doti-Spogli Endowed Chair of Free Enterprise at the school. Ned graduated from Columbia University with a bachelor’s degree in Economics and Philosophy. He previously spent 15 years in corporate operations and financial management. Ned has written hundreds of articles for and
Search Dividend Investor